Esperion Reports Second Quarter 2023 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Piper Sandler Starts SoFi Technologies (SOFI) at Overweight
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
- Six dead in 'stampede-like' incident at India temple, ANI says
Northland Upgrades Esperion Therapeutics (ESPR) to Market Perform. 'Potential Resolution of DSE Litigation as Catalysts'
August 1, 2023 2:01 PM EDTNorthland Capital Markets analyst Carl Byrnes upgraded Esperion Therapeutics (NASDAQ: ESPR) from Underperform to Market Perform with a price target of $2.00 (from $1.00).
The analyst comments "We are adjusting our rating to MP as we believe sNDA approvals in both the... More
